Literature DB >> 19250272

The relationship between thyroid function, serum monokine induced by interferon gamma and soluble interleukin-2 receptor in thyroid autoimmune diseases.

J Jiskra1, M Antosová, Z Límanová, Z Telicka, Z Lacinová.   

Abstract

Interactions between cytokines play an important role in the development of thyroid autoimmunity. Using enzyme-linked immunosorbent assay we investigated serum concentrations of soluble interleukin-2 receptor (sIL-2R), interferon-gamma, tumour necrosis factor (TNF)-alpha, interleukin (IL)-10, CD30, monokine induced by interferon-gamma (MIG), cytotoxic T lymphocyte antigen-4 and markers of apoptosis decoy receptor 3 and Bcl-2 in 28 patients with hyperthyroid Graves' disease (GD), 24 patients with untreated Hashimoto's thyroiditis (HT) and 15 healthy controls. TNF-alpha, IL-10 and sIL-2R were higher in GD compared with HT and controls (TNF-alpha: 8.79 in GD versus 2.54 pg/ml in HT, P = 0.01; IL-10: 10.00 versus 3.10 versus 3.10 pg/ml, P(1) < 0.001, P(2) = 0.005; sIL-2R: 1.26 versus 0.64 versus 0.46 ng/ml, P < 0.001). MIG and CD30 were higher in HT compared with controls (649.22 +/- 262.55 versus 312.95 +/- 143.35 pg/ml, P = 0.037, 6.57 +/- 2.35 versus 3.03 +/- 1.04 U/ml, P = 0.036 respectively). In GD sIL-2R decreased when the euthyroid state was achieved (1.31 +/- 0.64 versus 0.260 +/- 0.11, n = 12, P < 0.001). sIL-2R correlated positively with free thyroxine (FT4) (R = 0.521, P = 0.000) and negatively with thyroid stimulating hormone (TSH) (R = -0.472, P = 0.00132). MIG correlated negatively with FT4 (R = -0.573, P = 0.00234) and positively with TSH (R = 0.462, P = 0.0179). The results suggest that serum concentrations of sIL-2R and MIG are related to thyroid function rather than to activation of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250272      PMCID: PMC2759467          DOI: 10.1111/j.1365-2249.2009.03897.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy.

Authors:  I M Wakelkamp; M N Gerding; J W Van Der Meer; M F Prummel; W M Wiersinga
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.

Authors:  J Myśliwiec; A Kretowski; J Topolska; K Siewko; D Jakubczyk; M Szelachowska; A Mikita; I Kinalska
Journal:  Horm Metab Res       Date:  2001-12       Impact factor: 2.936

3.  Circulating chemokines in patients with autoimmune thyroid diseases.

Authors:  J Domberg; C Liu; L Chao; C Papewalis; C Pfleger; K Xu; H S Willenberg; D Hermsen; W A Scherbaum; N C Schloot; M Schott
Journal:  Horm Metab Res       Date:  2008-04-14       Impact factor: 2.936

Review 4.  Death and decoy receptors and p53-mediated apoptosis.

Authors:  M S Sheikh; A J Fornace
Journal:  Leukemia       Date:  2000-08       Impact factor: 11.528

5.  CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease.

Authors:  T Kouki; Y Sawai; C A Gardine; M E Fisfalen; M L Alegre; L J DeGroot
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

6.  DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus.

Authors:  Bing Han; Rafael Bojalil; Luis M Amezcua-Guerra; Rashidi Springall; Héctor Valderrama-Carvajal; Jiangping Wu; Hongyu Luo
Journal:  Int Immunol       Date:  2008-06-17       Impact factor: 4.823

Review 7.  Cytokines in thyroid autoimmunity.

Authors:  R A Ajjan; A P Weetman
Journal:  Autoimmunity       Date:  2003 Sep-Nov       Impact factor: 2.815

8.  Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease.

Authors:  Paola Romagnani; Mario Rotondi; Elena Lazzeri; Laura Lasagni; Michela Francalanci; Andrea Buonamano; Stefano Milani; Paolo Vitti; Luca Chiovato; Massimo Tonacchera; Antonio Bellastella; Mario Serio
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

9.  Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3).

Authors:  Ren-In You; Yung-Chi Chang; Po-Min Chen; Wei-Shu Wang; Tsui-Ling Hsu; Chih-Ya Yang; Chun-Ting Lee; Shie-Liang Hsieh
Journal:  Blood       Date:  2007-11-15       Impact factor: 22.113

10.  Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function.

Authors:  Juan J Díez; Angel Hernanz; Sonia Medina; Carmen Bayón; Pedro Iglesias
Journal:  Clin Endocrinol (Oxf)       Date:  2002-10       Impact factor: 3.478

View more
  4 in total

1.  Blood lymphocyte blastogenesis in patients with thyroid dysfunction: ex vivo response to mitogen activation and cyclosporin A.

Authors:  Garyphallia Papaioannou; Fotios V Michelis; Konstantinos Papamichael; Helen Karga; Ekaterini Tiligada
Journal:  Inflamm Res       Date:  2010-10-24       Impact factor: 4.575

2.  Fulminant hepatitis and elevated levels of sIL-2R in thyroid storm.

Authors:  Yuri Tanaka; Taisuke Uchida; Hideki Yamaguchi; Yohei Kudo; Tadato Yonekawa; Masamitsu Nakazato
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-09-27

3.  Peripheral blood lymphocyte apoptosis and its relationship with thyroid function tests in adolescents with hyperthyroidism due to Graves' disease.

Authors:  Maria Klatka; Ewelina Grywalska; Agata Surdacka; Jerzy Tarach; Janusz Klatka; Jacek Roliński
Journal:  Arch Med Sci       Date:  2012-11-07       Impact factor: 3.318

4.  Rapid Improvement of thyroid storm-related hemodynamic collapse by aggressive anti-thyroid therapy including steroid pulse: A case report.

Authors:  Hiroyuki Kiriyama; Eisuke Amiya; Masaru Hatano; Yumiko Hosoya; Hisataka Maki; Daisuke Nitta; Akihito Saito; Yasuyuki Shiraishi; Shun Minatsuki; Tatsuyuki Sato; Haruka Murakami; Masae Uehara; Katsunori Manaka; Noriko Makita; Masafumi Watanabe; Issei Komuro
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.